http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
개별검색 DB통합검색이 안되는 DB는 DB아이콘을 클릭하여 이용하실 수 있습니다.
통계정보 및 조사
예술 / 패션
<해외전자자료 이용권한 안내>
- 이용 대상 : RISS의 모든 해외전자자료는 교수, 강사, 대학(원)생, 연구원, 대학직원에 한하여(로그인 필수) 이용 가능
- 구독대학 소속 이용자: RISS 해외전자자료 통합검색 및 등록된 대학IP 대역 내에서 24시간 무료 이용
- 미구독대학 소속 이용자: RISS 해외전자자료 통합검색을 통한 오후 4시~익일 오전 9시 무료 이용
※ 단, EBSCO ASC/BSC(오후 5시~익일 오전 9시 무료 이용)
In order not to hinder the trend of promoting participatory forest management under the REDD-plus mechanism, we propose a simple method to support local stakeholders evaluating and selecting promising national programs as REDD-plus activities prior to the launch of activities. Program evaluation is done from the viewpoint of expectations for achieving (1) ‘triple-benefit’ consisting of emission reduction from mitigating deforestation and forest degradation, biodiversity conservation, and poverty alleviation,and (2) ‘feasibility’ when the programs would be practiced on the ground. The method is applicable for other countries.
We had the first committee meeting of the East Asia VLBI Consortium during the EAMA6 meeting held in Seoul. A VLBI network composed of telescopes in the East Asia region could provide extreme properties, and the coordination of them has been expected. The Committee of the East Asia VLBI Consortium is a standing committee to promote activities of the consortium, in which participating countries at present are China, Japan, and Korea over eight institutes/observatories. Here we introduce the Consortium and Committee.
In order not to hinder the trend of promoting participatory forest management under the REDD-plus mechanism, we propose a simple method to support local stakeholders evaluating and selecting promising national programs as REDD-plus activities prior to the launch of activities. Program evaluation is done from the viewpoint of expectations for achieving (1) 'triple-benefit' consisting of emission reduction from mitigating deforestation and forest degradation, biodiversity conservation, and poverty alleviation, and (2) 'feasibility' when the programs would be practiced on the ground. The method is applicable for other countries.
The VLBI Space Observatory Program (VSOP) is a worldwide project of one radio telescope in space with many ground radio telescopes. The concerted space VLBI network enables us to reveal high resolution and high quality images of radio sources. The space radio telescope is anticipated to be launched in January/February 1997, and collaborative observations have been coordinated. The basic parameters of the system and present status are given.
In order to utilize coal fly ash (hereafter:coal ash ) discharged from coal boiler as a material for civil engineering usage such as snow melter or soil improver, we have to prevent leaching hazardous elements such as fluorine, boron and heavy metals from the coal ash because the leaching concentrations of some elements in the ash exceed the Japanese standards for environmental soil quality. Through the laboratory experiments and mill trials, we confirmed that the leaching concentrations of fluorine, boron and heavy metals were maintained below their environmental standards by mixing with fixation chemicals and curing for a short time.
Purpose: To evaluate urination-related quality of life (QoL) in patients with an indwelling ureteral stent immediately after ureteroscopic lithotripsy (URSL) for upper urinary calculi. We compared the effects of loop-tail and pigtail ureteral stents on urination-related QoL. Materials and Methods: Of 135 patients who underwent URSL between May 2014 and March 2015 at our hospital, we retrospectively analyzed the records of 70 patients (42 men, 28 women; median age, 63 years) in whom the stent tail was positioned inside the bladder without crossing the midline and who completed the core lower urinary tract symptoms score (CLSS) questionnaire pre- and postoperatively. Results: There were significant differences in incomplete emptying (p=0.048) and bladder pain (p=0.041) between patients with loop-tail versus pigtail ureteral stents after URSL. In the multivariate analysis, stent type had a stronger association with incomplete emptying (p=0.022) and bladder pain (p=0.018) than age, sex, body mass index, stent side, operation time, diameter of ureteral access sheath, and stent type. Conclusions: Patients with loop-tail ureteral stents had better urination-related QoL in the immediate post-URSL stage than patients with pigtail stents.
( Nagamu Inoue ),( Kiyonori Kobayashi ),( Makoto Naganuma ),( Fumihito Hirai ),( Morio Ozawa ),( Dilek Arikan ),( Bidan Huang ),( Anne M. Robinson ),( Roopal B. Thakkar ),( Toshifumi Hibi ) 대한장연구학회 2017 Intestinal Research Vol.15 No.3
Background/Aims: Intestinal Behcet`s disease (BD) is an immune-mediated inflammatory disorder. We followed up the patients and evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through 100 weeks rolled over from the 52 week clinical trial (NCT01243671). Methods: Patients initiated adalimumab therapy at 160 mg at week 0, followed by 80 mg at week 2, followed by 40 mg every other week until the end of the study. Long-term safety and all adverse events (AEs) were examined. The efficacy was assessed on the basis of marked improvement (MI) and complete remission (CR) using a composite efficacy index, which combined global gastrointestinal symptoms and endoscopic assessments. Re-sults: Twenty patients were enrolled in this study; 15 patients received adalimumab treatment until study completion. The incidence of AEs through week 100 was 544.4 events/100 person-years, which was comparable to the incidence through week 52 (560.4 events/100 person-years). No unexpected trend was observed and adalimumab was well tolerated. At weeks 52 and 100, 60.0% and 40.0% of patients showed MI, respectively, and 20.0% and 15.0% of patients showed CR, respectively. Conclusions: This report demonstrates 2 years safety and effectiveness of adalimumab in intestinal BD patients. Patients with intestinal BD refractory to conventional treatment receiving up to 2 years of adalimumab treatment demonstrated safety outcomes consistent with the known profile of adalimumab, and the treatment led to sustained reduction of clinical and endoscopic disease activity. (Intest Res 2017;15:395-401)